|VENTURE FUNDING TOTAL||$8.94M|
|Series A, 3/10 |
Cross Road Biotech
Chosen as one of Spainâ€™s top 5 biotech investment opportunities, TCD is focused on creating the future of Oncology by developing innovative therapies that address unmet medical needs.
Established in 2005 and with one product, TCD-717, already in clinical trials the Company is positioning itself as Spainâ€™s Partner of Choice for Oncology drug discovery and development opportunities.
TCDâ€™s strong management team, its strategy of building its pipeline through in-licensing and partnerships and by leveraging resources through collaborations and outsourcing via premier Contract Research Organizations, allows TCD to be in the forefront of Oncology drug development while significantly lowering risks and costs.